PARP1 and ovarian carcinoma: Rucaparib was the second PARP inhibitor approved, receiving FDA accelerated approval in 2016 based on the findings of the ARIEL2 trial for patients with BRCA-mutated, relapsed ovarian cancer and, subsequently, approval as a maintenance therapy for patients with platinum-sensitive ovarian cancer based on the results of the ARIEL3 trial in 2018 [163].